8
Registered trials
3
Recruiting
8
Unique sponsors
8
Unique IMPs
5
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
N
Neurology/Psychiatry (ATC N)
1
B
Haematology (ATC B)
1
V
Various (ATC V)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
6 substances
Monoclonal antibody (neural)
1 substance
Supportive / diluent
1 substance
Phase III:
2
Phase II:
4
Phase I/II:
1
Phase I (Other):
1
Phase III
2 trials-
EndedAmylyx Pharmaceuticals Inc. CommercialPHENYLBUTYRATE, URSODOXICOLTAURINE
-
PendingNovartis Pharma AG CommercialNIO752; SODIUM CHLORIDE
Phase II
4 trials-
EndedFerrer Internacional S.A. Commercial(S)-N-(5-(4-(1-(BENZO[D][1,3]DIOXOL-5-YL)ETHYL)PIPERAZIN-1-YL)-1,3,4-THIADIAZOL-2-YL)ACETAMIDE, HYDROCHLORIDE SALT
-
RecruitingFundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer AcademicIZAFLORTAUCIPIR (18F)
-
RecruitingRegion Skane Academic2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
-
EndedUniversity Clinic Of Navarra AcademicIZAFLORTAUCIPIR (18F)
Phase I/II
1 trial-
RecruitingZRO Imaging AB CommercialIMP not specified
Phase I (Other)
1 trial-
EndedUCB Biopharma CommercialBEPRANEMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| UCB Biopharma | Commercial | 1 | Phase I (Other) | 0 |
| Ferrer Internacional S.A. | Commercial | 1 | Phase II | 0 |
| Amylyx Pharmaceuticals Inc. | Commercial | 1 | Phase III | 0 |
| Novartis Pharma AG | Commercial | 1 | Phase III | 0 |
| ZRO Imaging AB | Commercial | 1 | Phase I/II | 1 |
| Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer | Academic | 1 | Phase II | 1 |
| Region Skane | Academic | 1 | Phase II | 1 |
| University Clinic Of Navarra | Academic | 1 | Phase II | 0 |
New trials by year
2020
1
2023
1
2024
2
2025
2